<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:29:23Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8095051" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8095051</identifier>
        <datestamp>2021-05-13</datestamp>
        <setSpec>thebreast</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Breast</journal-id>
              <journal-id journal-id-type="iso-abbrev">Breast</journal-id>
              <journal-title-group>
                <journal-title>The Breast : Official Journal of the European Society of Mastology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0960-9776</issn>
              <issn pub-type="epub">1532-3080</issn>
              <publisher>
                <publisher-name>Elsevier</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8095051</article-id>
              <article-id pub-id-type="pmcid">PMC8095051</article-id>
              <article-id pub-id-type="pmc-uid">8095051</article-id>
              <article-id pub-id-type="pmid">33901921</article-id>
              <article-id pub-id-type="pii">S0960-9776(21)00351-9</article-id>
              <article-id pub-id-type="doi">10.1016/j.breast.2021.03.012</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="au1">
                  <name>
                    <surname>Clemons</surname>
                    <given-names>Mark</given-names>
                  </name>
                  <email>mclemons@toh.ca</email>
                  <xref rid="aff1" ref-type="aff">a</xref>
                  <xref rid="aff2" ref-type="aff">b</xref>
                  <xref rid="aff3" ref-type="aff">c</xref>
                  <xref rid="cor1" ref-type="corresp">∗</xref>
                </contrib>
                <contrib contrib-type="author" id="au2">
                  <name>
                    <surname>Fergusson</surname>
                    <given-names>Dean</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author" id="au3">
                  <name>
                    <surname>Joy</surname>
                    <given-names>Anil A.</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author" id="au4">
                  <name>
                    <surname>Thavorn</surname>
                    <given-names>Kednapa</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author" id="au5">
                  <name>
                    <surname>Meza-Junco</surname>
                    <given-names>Judith</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author" id="au6">
                  <name>
                    <surname>Hiller</surname>
                    <given-names>Julie Price</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author" id="au7">
                  <name>
                    <surname>Mackey</surname>
                    <given-names>John</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author" id="au8">
                  <name>
                    <surname>Ng</surname>
                    <given-names>Terry</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au9">
                  <name>
                    <surname>Zhu</surname>
                    <given-names>Xiaofu</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">d</xref>
                </contrib>
                <contrib contrib-type="author" id="au10">
                  <name>
                    <surname>Ibrahim</surname>
                    <given-names>Mohammed F.K.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au11">
                  <name>
                    <surname>Sienkiewicz</surname>
                    <given-names>Marta</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au12">
                  <name>
                    <surname>Saunders</surname>
                    <given-names>Deanna</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au13">
                  <name>
                    <surname>Vandermeer</surname>
                    <given-names>Lisa</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author" id="au14">
                  <name>
                    <surname>Pond</surname>
                    <given-names>Gregory</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">e</xref>
                </contrib>
                <contrib contrib-type="author" id="au15">
                  <name>
                    <surname>Basulaiman</surname>
                    <given-names>Bassam</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au16">
                  <name>
                    <surname>Awan</surname>
                    <given-names>Arif</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author" id="au17">
                  <name>
                    <surname>Pitre</surname>
                    <given-names>Lacey</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">f</xref>
                </contrib>
                <contrib contrib-type="author" id="au18">
                  <name>
                    <surname>Nixon</surname>
                    <given-names>Nancy A.</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">g</xref>
                </contrib>
                <contrib contrib-type="author" id="au19">
                  <name>
                    <surname>Hutton</surname>
                    <given-names>Brian</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">c</xref>
                </contrib>
                <contrib contrib-type="author" id="au20">
                  <name>
                    <surname>Hilton</surname>
                    <given-names>John F.</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">a</xref>
                  <xref rid="aff2" ref-type="aff">b</xref>
                </contrib>
                <on-behalf-of>on behalf of the </on-behalf-of>
                <contrib contrib-type="author">
                  <collab>REThinking Clinical Trials (REaCT) investigators</collab>
                </contrib>
                <aff id="aff1"><label>a</label>Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada</aff>
                <aff id="aff2"><label>b</label>Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada</aff>
                <aff id="aff3"><label>c</label>Clinical Epidemiology Program, Ottawa Hospital Research Institute and School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada</aff>
                <aff id="aff4"><label>d</label>Division of Medical Oncology, Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canada</aff>
                <aff id="aff5"><label>e</label>Department of Oncology, McMaster University, Hamilton, Canada</aff>
                <aff id="aff6"><label>f</label>Department of Oncology, Northeast Cancer Centre, Sudbury, Canada</aff>
                <aff id="aff7"><label>g</label>Division of Medical Oncology, Department of Oncology, University of Alberta, Tom Baker Cancer Centre, Calgary, Canada</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>∗</label>Corresponding author. Division of Medical Oncology Ottawa Hospital Research Institute, 501 Smyth Road, Box 912, Ottawa, Ontario, Canada. <email>mclemons@toh.ca</email></corresp>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>01</day>
                <month>4</month>
                <year>2021</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
              <pub-date pub-type="collection">
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>01</day>
                <month>4</month>
                <year>2021</year>
              </pub-date>
              <volume>58</volume>
              <fpage>42</fpage>
              <lpage>49</lpage>
              <history>
                <date date-type="received">
                  <day>30</day>
                  <month>11</month>
                  <year>2020</year>
                </date>
                <date date-type="rev-recd">
                  <day>23</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>29</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 The Authors</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
                </license>
              </permissions>
              <abstract id="abs0010">
                <sec>
                  <title>Background</title>
                  <p>Primary febrile neutropenia (FN) prophylaxis with ciprofloxacin or granulocyte-colony stimulating factors (G-CSF) is recommended with docetaxel-cyclophosphamide (TC) chemotherapy for early-stage breast cancer (EBC). A pragmatic randomised trial compared the superiority of G-CSF to ciprofloxacin and a cost-utility analysis were conducted.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>EBC patients receiving TC chemotherapy were randomised to ciprofloxacin or G-CSF. The primary outcome was a composite of FN and non-FN treatment-related hospitalisation. Secondary outcomes included; rates of FN, non-FN treatment-related hospitalisation, chemotherapy dose reductions/delays/discontinuations. Primary analysis was performed with the intention to treat population. Cost-utility analyses were conducted from the Canadian public payer perspective.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>458 eligible patients were randomised: 228 to ciprofloxacin and 230 to G-CSF. For the primary endpoint there was non-statistically significant difference (Risk difference = −6.7%, 95%CI = −13.5%–0.1%, p = 0.061) between ciprofloxacin patients (46,20.2%) and G-CSF (31,13.5%). Patients receiving ciprofloxacin were more likely to experience FN (36/228, 15.8% vs 13/230, 5.7%) than patients receiving G-CSF (p &lt; 0.001). Non-FN treatment-related hospitalisation occurred in 40/228 (17.5%) of ciprofloxacin patients vs 28/230 (12.2%) of G-CSF patients (p = 0.12). There were no differences in other secondary outcomes. G-CSF was associated with an incremental cost-effectiveness ratio of C$1,760,796 per one quality-adjusted life year gained.</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p>The primary endpoint of superiority of G-CSF over ciprofloxacin was not demonstrated. While there were reduced FN rates with G-CSF, there were no differences in chemotherapy dose delays/reductions or discontinuations. With the commonly used willingness to pay value of C$50,000/QALY, G-CSF use was not cost-effective compared to ciprofloxacin and deserves scrutiny from the payer perspective.</p>
                </sec>
              </abstract>
              <abstract abstract-type="author-highlights" id="abs0015">
                <title>Highlights</title>
                <p>
                  <list list-type="simple" id="ulist0010">
                    <list-item id="u0010">
                      <label>•</label>
                      <p id="p0010">Primary febrile neutropenia (FN) prophylaxis is indicated for docetaxel-cyclophosphamide (TC) chemotherapy.</p>
                    </list-item>
                    <list-item id="u0015">
                      <label>•</label>
                      <p id="p0015">In this multicentre trial 458 breast cancer patients receiving TC chemotherapy were randomised to ciprofloxacin or to G-CSF.</p>
                    </list-item>
                    <list-item id="u0020">
                      <label>•</label>
                      <p id="p0020">For the primary endpoint of FN and non-FN treatment-related hospitalizations, G-CSF was not superior over ciprofloxacin.</p>
                    </list-item>
                    <list-item id="u0025">
                      <label>•</label>
                      <p id="p0025">While there were reduced FN rates with G-CSF, the incremental cost-effectiveness ratio was C$1,760,796 per one QALYWALY gained.</p>
                    </list-item>
                  </list>
                </p>
              </abstract>
              <kwd-group id="kwrds0010">
                <title>Keywords</title>
                <kwd>Docetaxel-cyclophosphamide</kwd>
                <kwd>Breast cancer</kwd>
                <kwd>Febrile neutropenia</kwd>
                <kwd>G-CSF</kwd>
                <kwd>Ciprofloxacin</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec id="sec1">
              <label>1</label>
              <title>Introduction</title>
              <p id="p0030">Docetaxel-cyclophosphamide (TC) chemotherapy is commonly used for early stage breast cancer (EBC) [<xref rid="bib1" ref-type="bibr">1</xref>]. Due to the risk of neutropenia and associated consequences (including febrile neutropenia [FN], non-FN treatment-related hospitalisations, chemotherapy delays/dose reductions/discontinuation), evidence-based guidelines recommend that TC is co-administered with primary FN prophylaxis [<xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>]. While ciprofloxacin was mainly used in the definitive trial [<xref rid="bib1" ref-type="bibr">1</xref>], in clinical practice, granulocyte colony-stimulating factors (G-CSF) (e.g. filgrastim [Neupogen™, Grastofil™] [<xref rid="bib7" ref-type="bibr">7</xref>] or peg-filgrastim [Neulasta™] are commonly used [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib9" ref-type="bibr">9</xref>].</p>
              <p id="p0035">Despite differences in cost, route of administration and toxicity profiles between ciprofloxacin and G-CSF, the optimal choice of agent has never been definitively evaluated [<xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>]. In the absence of prospective comparisons, the choice of agent should be based on a full discussion between the patient and health care provider. This discussion should reflect; drug side effects [<xref rid="bib13" ref-type="bibr">13</xref>,<xref rid="bib14" ref-type="bibr">14</xref>], subcutaneous administration of G-CSF, and expense (C$ 1920/cycle Neupogen, C$ 1440/cycle Grastofil and C$ 2380/cycle Neulasta™) [<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib16" ref-type="bibr">16</xref>]. In practice, however, the choice is usually based on physician preference [<xref rid="bib10" ref-type="bibr">10</xref>].</p>
              <p id="p0040">We previously confirmed the feasibility of performing a randomised clinical trial using an oral consent methodology [<xref rid="bib17" ref-type="bibr">17</xref>] for comparing ciprofloxacin with G-CSF in patients receiving TC [<xref rid="bib12" ref-type="bibr">12</xref>]. This pilot study was then expanded to compare efficacy outcomes. We report on the expanded study. The primary outcome is a composite endpoint comprised of FN and non-FN treatment-related hospitalisations. This endpoint was chosen as a previous patient survey showed this was the outcome of greatest personal importance [<xref rid="bib10" ref-type="bibr">10</xref>].</p>
            </sec>
            <sec id="sec2">
              <label>2</label>
              <title>Methods</title>
              <p id="p0045">This open-label, superiority trial was performed at four Canadian cancer centres. Eligible patients had EBC, no prior history of chemotherapy, and were planned to receive 4 cycles of adjuvant TC chemotherapy. Exclusion criteria included contraindications to either G-CSF or ciprofloxacin. Patients were approached for study participation by their oncologist. The study was approved by the local Research Ethics Boards and registered on <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov" id="intref0010">clinicaltrials.gov</ext-link> (NCT02816112) [<xref rid="bib18" ref-type="bibr">18</xref>].</p>
              <sec id="sec2.1">
                <label>2.1</label>
                <title>Randomisation</title>
                <p id="p0050">Consented patients were randomised 1:1 to ciprofloxacin (500 mg PO BID for 7–14 days starting 5 days after chemotherapy) or G-CSF (patients, with their physicians, could choose the type, dose, and duration of G-CSF use, including biosimilars) as primary FN prophylaxis for each chemotherapy cycle. Following confirmation of the feasibility of the oral consent methodology [<xref rid="bib12" ref-type="bibr">12</xref>,<xref rid="bib19" ref-type="bibr">19</xref>] (Version 28/Aug/2014, NCT02173262, n = 186), a protocol amendment (19/Oct/2016, NCT02816112) allowed study expansion to compare the efficacy of ciprofloxacin with G-CSF. Randomisation was performed using a permuted block design with blocks of variable sizes stratified by centre using a web-based application developed by The Ottawa Methods Centre.</p>
                <p id="p0055">Patients received ciprofloxacin or G-CSF (Neupogen™, Neulasta™: Amgen, Thousand Oaks CA, USA, or Grastofil™, Apotex, Toronto, Canada). Study drugs were funded through either <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100009142</institution-id><institution>Cancer Care Ontario</institution></institution-wrap></funding-source> (patients over 65) or through third party insurance co-pay programs (Ontario and Alberta). Follow-up visits occurred as per usual care. Outcome data were collected from case report forms and electronic health records.</p>
              </sec>
              <sec id="sec2.2">
                <label>2.2</label>
                <title>Study hypotheses</title>
                <p id="p0060">The proportion of patients with the composite endpoint of FN or non-FN treatment-related hospitalisations will be lower for patients treated with G-CSF.</p>
              </sec>
              <sec id="sec2.3">
                <label>2.3</label>
                <title>Outcomes</title>
                <p id="p0065">The primary outcome was the rate of a composite measure of documented, laboratory confirmed FN [<xref rid="bib20" ref-type="bibr">20</xref>] or non-FN treatment-related hospital admission. Secondary outcomes included; FN rates, non-FN treatment-related hospitalisation rates, proportion of patients who required chemotherapy dose delays/reductions/discontinuation. Rates of laboratory confirmed <italic>Clostridium difficile</italic> infections or other microbiologic infections were collected.</p>
              </sec>
              <sec id="sec2.4">
                <label>2.4</label>
                <title>Statistical analysis</title>
                <p id="p0070">Patient characteristics and outcomes were summarised using descriptive statistics. All outcomes were assessed from the date of randomisation until 28 days (inclusive) after the last cycle of TC chemotherapy. Primary analysis was based on the intention-to-treat (ITT) principle, which included all patients in the treatment group to which they were allocated, even if they did not receive treatment or were non-compliant. A supportive analysis was performed on the per protocol (PP) population, which included those who received initial treatment as per their randomised allocation. The primary analysis was based on a two-sided, Fisher’s exact test with statistical significance defined at the p = 0.05 level. Absolute risk difference and 95% confidence intervals were calculated between both treatment groups using the Score (Wilson) method. Pre-planned subgroup analyses included: treatment centre (Ottawa vs. others) and age (&lt;65 vs. 65+). Logistic regression analyses, adjusted for stratification factors, were also performed. All statistical analysis was carried out using SAS version-9 or higher for Windows (Cary, NC) or R version 3.2.2 (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org" id="intref0015">www.r-project.org</ext-link>). or higher. Of note, the preliminary efficacy data of the feasibility study [<xref rid="bib12" ref-type="bibr">12</xref>]. was not assessed to ensure the type I error was not impacted.</p>
              </sec>
              <sec id="sec2.5">
                <label>2.5</label>
                <title>Sample size</title>
                <p id="p0075">An informal survey of medical oncologists from participating centres in February 2016 asked what they felt would be the minimally important effect of G-CSF needed to be deemed superior to ciprofloxacin. The published rates of FN in patients receiving primary FN prophylaxis cited in the survey ranged from 5% to 8% [<xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>], thus, if the primary outcome rate in patients administered ciprofloxacin was estimated to be 8%, survey respondents identified that a rate of 2% or less of patients receiving G-CSF would be required to change practice universally. Hence, assuming primary outcome rates of 8% versus 2% for patients administered ciprofloxacin and G-CSF, 80% power and a two-sided alpha of 5%, the required overall sample size was 412 people (206 per treatment group). To account for 5% non-compliance with the protocol, the target sample size was 456 patients (228 per arm).</p>
              </sec>
              <sec id="sec2.6">
                <label>2.6</label>
                <title>Health economic evaluation</title>
                <p id="p0080">We conducted a cost-utility analysis utilising a decision tree and patient-level data from the trial (<xref rid="fig1" ref-type="fig">Fig. 1</xref> and <xref rid="appsec1" ref-type="sec">Supplemental Table 1</xref>). The time horizon of the model was three months to align with the trial follow-up, discounting was therefore not required. We did not use a lifetime horizon because G-CSF and ciprofloxacin are supportive care therapies in the breast cancer setting without survival benefits [<xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib22" ref-type="bibr">22</xref>]. FN and non-FN treatment-related hospitalisations data were taken from the trial. Health outcome was shown as quality-adjusted life year (QALY), that was estimated based on the published health utility values and the area under the curve method. Costs were estimated from the Ontario Ministry of Health perspective and expressed in 2020 Canadian dollars (C$). Our model included the costs of G-CSF, ciprofloxacin, physicians, hospitalisation, inpatient and outpatient FN management. Incremental cost-effectiveness ratios (ICERs) were shown as the incremental cost per QALY gained. We performed a series of one-way and probabilistic sensitivity analyses (PSA) to assess the robustness of study results. A scenario analysis was carried out to assess the impact of the proportion of peg-filgrastim vs. filgrastim.<fig id="fig1"><label>Fig. 1</label><caption><p>Decision tree structure.</p></caption><alt-text id="alttext0020">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p>
              </sec>
            </sec>
            <sec id="sec3">
              <label>3</label>
              <title>Results</title>
              <p id="p0085">The trial enrolled from September 18, 2014 to November 19, 2019. Of 458 eligible patients, 228 were randomised to ciprofloxacin and 230 to G-CSF (CONSORT flow diagram, <xref rid="fig2" ref-type="fig">Fig. 2</xref>). Of 458 patients, 15 (7 ciprofloxacin; 8 G-CSF) withdrew prior to start of treatment (<xref rid="fig2" ref-type="fig">Fig. 2</xref>). In total, 443 (221 ciprofloxacin; 222 G-CSF) patients received treatment as part of this trial. Reasons for discontinuation of study treatments are shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref>.<fig id="fig2"><label>Fig. 2</label><caption><p>Study CONSORT diagram.</p></caption><alt-text id="alttext0025">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p>
              <p id="p0090">Baseline characteristics of the randomised patients are presented in <xref rid="tbl1" ref-type="table">Table 1</xref>. Median age was 58 years (range 30–84). The total number of chemotherapy cycles given were 819 in the ciprofloxacin arm and 849 in the G-CSF arm. Median (interquartile range) durations on study were 90 days (range 46–98) and 92 days (range 68–103) for ciprofloxacin and G-CSF patients, respectively.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Patient enrolment and baseline characteristics.</p></caption><alt-text id="alttext0040">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Overall</th><th>Ciprofloxacin</th><th>G-CSF</th></tr></thead><tbody><tr><td align="left"><bold>N</bold></td><td align="left">458</td><td align="left">228</td><td align="left">230</td></tr><tr><td align="left">Mean age (std dev)<break/>Median (range)</td><td align="left">57.7 (10.7)<break/>58 (30, 84)</td><td align="left">59.0 (10.9)<break/>60 (30, 84)</td><td align="left">56.4 (10.4)<break/>57 (31, 81)</td></tr><tr><td align="left"><bold>Type, dose and number of injections of G-CSF∗: n (%)</bold></td><td align="left">–</td><td align="left">–</td><td align="left">147</td></tr><tr><td align="left">Pegfilgrastim (6 mg)<break/>Filgrastim (300mcg/5 d)<break/>Filgrastim (300mcg/7 d)<break/>Filgrastim (300mcg/10 d)<break/>Filgrastim (480mcg/5 d)<break/>Filgrastim (480mcg/7 d)<break/>Filgrastim (480mcg/10 d)<break/>Dose Unknown</td><td/><td/><td align="left">4 (2.7)<break/>79 (53.7)<break/>34 (23.1)<break/>26 (17.7)<break/>1 (0.7)<break/>1 (0.7)<break/>2 (1.4)<break/>83 (36.1)</td></tr><tr><td align="left"><bold>Total Cycles of Treatment for all patients</bold><break/>0<break/>1<break/>2<break/>3<break/>4</td><td align="left"><break/>15 (3.3)<break/>26 (5.7)<break/>12 (2.6)<break/>18 (3.9)<break/>387 (84.5)</td><td align="left"><break/>7 (3.1)<break/>14 (6.1)<break/>8 (3.5)<break/>9 (4.0)<break/>190 (83.3)</td><td align="left"><break/>8 (3.5)<break/>12 (5.2)<break/>4 (1.7)<break/>9 (3.9)<break/>197 (85.7)</td></tr></tbody></table><table-wrap-foot><fn id="tspara0015"><p>TC = docetaxel/cyclophosphamide.</p></fn><fn id="tspara0020"><p>∗ Data was available on the types of growth factors prescribed at one centre (Ottawa Hospital) only (n = 147). Biosimilar preparations of both filgrastim and pegfilgrastim were allowed.</p></fn></table-wrap-foot></table-wrap></p>
              <sec id="sec3.1">
                <label>3.1</label>
                <title>Primary outcomes</title>
                <p id="p0095">FN occurred in 36 (15.8%) ciprofloxacin patients and 13 (5.7%) G-CSF patients (RD = −10.1%, 95%CI = −15.7% to −4.5%, p-value&lt;0.001) (<xref rid="tbl2" ref-type="table">Table 2</xref>, <xref rid="fig3" ref-type="fig">Fig. 3</xref>). There were 40 (17.5%) ciprofloxacin patients who were hospitalised for any reason, compared with 28 (12.2%) G-CSF patients (RD = −5.4%, 95%CI = −11.9%–1.1%, p-value = 0.12). For the primary composite endpoint, a total of 46 (20.2%) ciprofloxacin patients experienced FN or were hospitalised, whereas 31 (13.5%) G-CSF patients experienced FN or were hospitalised. The risk difference was −6.7%, with a 95%CI of −13.5%–0.1%, p-value = 0.061 (<xref rid="fig3" ref-type="fig">Fig. 3</xref>, <xref rid="tbl2" ref-type="table">Table 2</xref> and <xref rid="appsec1" ref-type="sec">Supplemental Tables 2 and 3</xref>). Results were similar in the PP analysis (<xref rid="appsec1" ref-type="sec">Supplemental Tables 2 and 3</xref>). After adjusting for age (&gt;65 versus ≤ 65) and treatment centre, the odds ratio (95%CI) for developing FN or hospitalisation was 1.52 (95%CI 0.91 to 2.53; p = 0.11) for patients treated with ciprofloxacin. In other words, patients on the ciprofloxacin arm had increased odds of experiencing the primary outcome event, adjusted for stratification factors. Subgroup analyses are presented in <xref rid="appsec1" ref-type="sec">Supplemental Tables 3 and 4</xref><table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Clinical endpoints, Per Protocol Analysis.</p></caption><alt-text id="alttext0045">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Outcome</th><th>Ciprofloxacin,<break/>N (%)</th><th>G-CSF<break/>N (%)</th><th>Risk Difference (95% CI)</th><th>p-value</th></tr></thead><tbody><tr><td align="left">N</td><td align="left">221</td><td align="left">222</td><td/><td/></tr><tr><td align="left"><bold>Primary Endpoint</bold></td><td/><td/><td/><td/></tr><tr><td align="left">FN or Treatment-related hospitalisation</td><td align="left">43 (19.5)</td><td align="left">29 (13.1)</td><td align="left">−6.4% (−13.2, 0.5)</td><td align="left">0.073</td></tr><tr><td align="left"><bold>Secondary Endpoints</bold></td><td/><td/><td/><td/></tr><tr><td align="left">Febrile Neutropenia</td><td align="left">36 (16.3)</td><td align="left">13 (5.9)</td><td align="left">−10.4% (−16.2, −4.7)</td><td align="left">&lt;0.001</td></tr><tr><td align="left">Treatment-related Hospitalisation</td><td align="left">37 (16.7)</td><td align="left">25 (11.3)</td><td align="left">−5.5% (−11.9, 1.0)</td><td align="left">0.10</td></tr><tr><td align="left">Chemotherapy dose reduction</td><td align="left">23 (10.4)</td><td align="left">21 (9.5)</td><td align="left">−1.0% (−6.5, 4.6)</td><td align="left">0.75</td></tr><tr><td align="left">Chemotherapy discontinuation</td><td align="left">17 (7.7)</td><td align="left">8 (3.6)</td><td align="left">−4.1% (−8.4, 0.2)</td><td align="left">0.067</td></tr><tr><td align="left">Chemotherapy dose delay</td><td align="left">8 (3.6)</td><td align="left">9 (4.1)</td><td align="left">0.4% (−3.1, 4.0)</td><td align="left">1.00</td></tr><tr><td align="left">Microinfection</td><td align="left">8 (3.6)</td><td align="left">12 (5.4)</td><td align="left">1.8% (−2.1, 5.7)</td><td align="left">0.49</td></tr><tr><td align="left"><bold>Any Event</bold></td><td align="left">99 (44.8)</td><td align="left">76 (34.2)</td><td align="left">−10.6% (−19.6, −1.5)</td><td align="left">0.026</td></tr></tbody></table><table-wrap-foot><fn><p>FN=Febrile neutropenia.</p></fn></table-wrap-foot></table-wrap><fig id="fig3"><label>Fig. 3</label><caption><p>Forest Plot of clinical endpoints, ITT Population.</p></caption><alt-text id="alttext0030">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig></p>
                <p id="p0100">Of the 36 patients in the ciprofloxacin group that experienced FN, 30 were hospitalised and 6 had outpatient management. Of 13 patients with FN while on G-CSF, 9 were hospitalised and 4 were managed as outpatients.</p>
              </sec>
              <sec id="sec3.2">
                <label>3.2</label>
                <title>Cycle data</title>
                <p id="p0105">Events were most frequent during the first cycle of therapy (<xref rid="tbl3" ref-type="table">Table 3</xref>). Amongst ciprofloxacin patients, 10.4% and 11.3% respectively experienced FN or non-FN treatment-related hospitalisation during the first cycle, compared with 2.6% and 2.6% in the fourth cycle. Similarly, amongst G-CSF patients, 4.5% and 6.8% experienced FN or non-FN treatment-related hospitalisations during cycle 1, while 1.5% and 1.0% did so during cycle 4.<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p><bold>Clinical endpoints, by Cycle, ITT Analysis</bold>.</p></caption><alt-text id="alttext0050">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th><hr/></th><th colspan="4">Ciprofloxacin<hr/></th><th colspan="4">G-CSF<hr/></th></tr><tr><th>Cycle</th><th>1</th><th>2</th><th>3</th><th>4</th><th>1</th><th>2</th><th>3</th><th>4</th></tr></thead><tbody><tr><td align="left">n (%)</td><td align="left">221</td><td align="left">203</td><td align="left">199</td><td align="left">196</td><td align="left">222</td><td align="left">214</td><td align="left">211</td><td align="left">202</td></tr><tr><td align="left">Febrile Neutropenia</td><td align="left">23 (10.4)</td><td align="left">17 (8.4)</td><td align="left">9 (4.5)</td><td align="left">5 (2.6)</td><td align="left">10 (4.5)</td><td align="left">8 (3.7)</td><td align="left">4 (1.9)</td><td align="left">3 (1.5)</td></tr><tr><td align="left">Treatment-related Hospitalisation</td><td align="left">25 (11.3)</td><td align="left">10 (4.9)</td><td align="left">4 (2.0)</td><td align="left">5 (2.6)</td><td align="left">15 (6.8)</td><td align="left">8 (3.7)</td><td align="left">7 (3.3)</td><td align="left">2 (1.0)</td></tr><tr><td align="left">Chemotherapy dose reduction</td><td align="left">0</td><td align="left">19 (9.4)</td><td align="left">12 (6.0)</td><td align="left">6 (3.1)</td><td align="left">0</td><td align="left">18 (8.4)</td><td align="left">12 (5.7)</td><td align="left">9 (4.5)</td></tr><tr><td align="left">Chemotherapy discontinuation</td><td align="left">18 (8.1)</td><td align="left">4 (2.0)</td><td align="left">3 (1.5)</td><td align="left">8 (4.1)</td><td align="left">8 (3.6)</td><td align="left">3 (1.4)</td><td align="left">5 (2.4)</td><td align="left">9 (4.5)</td></tr><tr><td align="left">Chemotherapy dose delay</td><td align="left">0</td><td align="left">9 (4.4)</td><td align="left">5 (2.5)</td><td align="left">2 (1.0)</td><td align="left">0</td><td align="left">5 (2.3)</td><td align="left">9 (4.3)</td><td align="left">6 (3.0)</td></tr><tr><td align="left">Microinfection</td><td align="left">5 (2.3)</td><td align="left">5 (2.5)</td><td align="left">2 (1.0)</td><td align="left">1 (0.5)</td><td align="left">6 (2.7)</td><td align="left">6 (2.8)</td><td align="left">1 (0.5)</td><td align="left">1 (0.5)</td></tr></tbody></table></table-wrap></p>
              </sec>
              <sec id="sec3.3">
                <label>3.3</label>
                <title>Secondary outcomes</title>
                <p id="p0110">Overall, 15.7% of patients experienced a dose reduction, 12.7% discontinued chemotherapy, and 7.4% experienced a dose delay. The most common reasons included non-neutropenic fever, peripheral neuropathy, and diarrhoea. No statistically significant difference was observed in the rates of chemotherapy dose reductions (p = 0.90), discontinuations (p = 0.26), dose delays (p = 0.59) or microinfections (p = 0.83) (<xref rid="fig3" ref-type="fig">Fig. 3</xref> and <xref rid="appsec1" ref-type="sec">Supplemental Table 3</xref>). Events were more common in earlier treatment cycles. In the ITT population, 24/458 (5.2%) patients experienced a laboratory confirmed microinfection. Three patients experienced <italic>C. difficile</italic> (2-ciprofloxacin; 1-G-CSF) and 1 G-CSF patient grew streptococci.</p>
                <p id="p0115">When combining all primary and secondary endpoints, 102/228 patients on ciprofloxacin (44.7%) had at least one primary or secondary endpoint event, compared with 78/230 (33.9%) of G-CSF patients (Fisher’s exact test, RD = −10.8%, 95%CI = −10.8% to −1.9%, p = 0.022) (<xref rid="fig3" ref-type="fig">Fig. 3</xref>).</p>
              </sec>
              <sec id="sec3.4">
                <label>3.4</label>
                <title>Cost-utility results</title>
                <p id="p0120">G-CSF was associated with higher cost (C$4005 vs. C$2581) and improved QALYs (0.1783 vs. 0.1774) compared to ciprofloxacin, with an estimated ICER of C$1,760,796/QALY. The estimated ICERs increased with the larger proportions of peg-filgrastim (<xref rid="tbl4" ref-type="table">Table 4</xref>). The cost-effectiveness results were highly sensitive to the unit cost of G-CSF, the relative risk of FN, and the relative risk of treatment-related hospitalisation (<xref rid="fig4" ref-type="fig">Fig. 4</xref>). The higher cost of G-CSF, the less likely that G-CSF would be cost-effective. By contrast, the greater effectiveness of G-CSF in reducing FN or treatment-related hospitalisation, the more likely that G-CSF would be cost-effective. Results of the PSA show that G-CSF was associated with increased cost and improved QALYs in the majority of the 5000 simulations (<xref rid="appsec1" ref-type="sec">Supplemental Fig. 1a</xref>). Regardless of the willingness-to-pay values, ciprofloxacin always had the greater probabilities of being a cost-effective option than G-CSF (<xref rid="appsec1" ref-type="sec">Supplemental Fig. 1b</xref>).<table-wrap position="float" id="tbl4"><label>Table 4</label><caption><p>Cost-utility analysis results.</p></caption><alt-text id="alttext0055">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Analysis</th><th>Treatment</th><th>Average<break/>Cost (C$)</th><th>Average QALYs</th><th>Incremental<break/>Cost (C$)</th><th>Incremental QALYs</th><th>ICER, C$/QALY</th></tr></thead><tbody><tr><td align="left" rowspan="2">Base case Pegfilgrastim 2.7%</td><td align="left">G-CSF</td><td align="left">4005</td><td align="left">0.1783</td><td align="left" rowspan="2">1424</td><td align="left" rowspan="2">0.0008</td><td align="left" rowspan="2">1,760,796</td></tr><tr><td align="left">Ciprofloxacin</td><td align="left">2581</td><td align="left">0.1774</td></tr><tr><td align="left" rowspan="2">Scenario analysis<break/>Pegfilgrastim 0%</td><td align="left">G-CSF</td><td align="left">3881</td><td align="left">0.1784</td><td align="left" rowspan="2">1298</td><td align="left" rowspan="2">0.0008</td><td align="left" rowspan="2">1,608,322</td></tr><tr><td align="left">Ciprofloxacin</td><td align="left">2583</td><td align="left">0.1776</td></tr><tr><td align="left" rowspan="2">Scenario analysis<break/>Pegfilgrastim 25%</td><td align="left">G-CSF</td><td align="left">4355</td><td align="left">0.1799</td><td align="left" rowspan="2">1779</td><td align="left" rowspan="2">0.0008</td><td align="left" rowspan="2">2,183,394</td></tr><tr><td align="left">Ciprofloxacin</td><td align="left">2576</td><td align="left">0.1791</td></tr><tr><td align="left" rowspan="2">Scenario analysis<break/>Pegfilgrastim 50%</td><td align="left">G-CSF</td><td align="left">4800</td><td align="left">0.1790</td><td align="left" rowspan="2">2232</td><td align="left" rowspan="2">0.0008</td><td align="left" rowspan="2">2,804,370</td></tr><tr><td align="left">Ciprofloxacin</td><td align="left">2568</td><td align="left">0.1782</td></tr><tr><td align="left" rowspan="2">Scenario analysis<break/>Pegfilgrastim 75%</td><td align="left">G-CSF</td><td align="left">5221</td><td align="left">0.1790</td><td align="left" rowspan="2">2636</td><td align="left" rowspan="2">0.0008</td><td align="left" rowspan="2">3,232,484</td></tr><tr><td align="left">Ciprofloxacin</td><td align="left">2585</td><td align="left">0.1782</td></tr><tr><td align="left" rowspan="2">Scenario analysis<break/>Pegfilgrastim 100%</td><td align="left">G-CSF</td><td align="left">5611</td><td align="left">0.1786</td><td align="left" rowspan="2">3036</td><td align="left" rowspan="2">0.0008</td><td align="left" rowspan="2">3,765,911</td></tr><tr><td align="left">Ciprofloxacin</td><td align="left">2576</td><td align="left">0.1778</td></tr></tbody></table></table-wrap><fig id="fig4"><label>Fig. 4</label><caption><p>One-way sensitivity analysis results.</p></caption><alt-text id="alttext0035">Fig. 4</alt-text><graphic xlink:href="gr4"/></fig></p>
              </sec>
            </sec>
            <sec id="sec4">
              <label>4</label>
              <title>Discussion</title>
              <p id="p0125">TC chemotherapy is usually co-administered with primary FN prophylaxis. A systematic review showed FN rates were reduced from 27% to 5% by primary FN prophylaxis [<xref rid="bib11" ref-type="bibr">11</xref>] but was limited by the retrospective nature of the trials involved. Hence the optimal form of prophylaxis is unknown [<xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>]. Indeed, the original study leading to TC approval did not specify whether prophylaxis was used [<xref rid="bib1" ref-type="bibr">1</xref>] and it was not until a subsequent publication when it became clear that most patients received prophylactic ciprofloxacin [<xref rid="bib23" ref-type="bibr">23</xref>]. To our knowledge, this is the only randomised trial to prospectively address this important clinical question. In this study the primary outcome of a composite of FN and non-FN treatment-related hospitalisations was chosen because EBC patients have stated that both were the outcomes of greatest importance to them [<xref rid="bib10" ref-type="bibr">10</xref>]. Our study did not demonstrate the superiority of G-CSF over ciprofloxacin. Our cost-utility analysis also showed that G-CSF was not cost-effective compared to ciprofloxacin at a commonly used willingness-to-pay threshold of C$50,000/QALY.</p>
              <p id="p0130">These finding are pertinent for several reasons. First, was a recent publication evaluating the omission of peg-filgrastim prophylaxis with the taxane component of dose-dense AC and paclitaxel [<xref rid="bib24" ref-type="bibr">24</xref>]. In this single arm study omission of routine peg-filgrastim was safe and feasible and associated with a 95.7% reduction in the use of peg-filgrastim. Second, the report from the most recent ASCO Clinical Practice Guideline Update for the Use of WBC Growth Factors [<xref rid="bib25" ref-type="bibr">25</xref>] states that, "Prophylactic use of CSFs to reduce the risk of FN is warranted when the risk of FN is approximately 20% or higher and no other equally effective and safe regimen that does not require CSFs is available”. Given that the rate of FN in the current study with ciprofloxacin use was 15%, this is below the 20% threshold stated in this guideline. Finally, with the commonly used willingness to pay value of C$50,000/QALY, the use of G-CSF was not cost-effective compared to ciprofloxacin and deserves great scrutiny from the payer perspective.</p>
              <p id="p0135">It is challenging to compare our findings with those in the literature, as past studies vary in the type of outcome they report (FN rates, neutropenia rates) and also in the type of analysis reported (by proportion of patients or per cycle of chemotherapy) [<xref rid="bib2" ref-type="bibr">[2]</xref>, <xref rid="bib3" ref-type="bibr">[3]</xref>, <xref rid="bib4" ref-type="bibr">[4]</xref>,<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib23" ref-type="bibr">23</xref>,<xref rid="bib26" ref-type="bibr">[26]</xref>, <xref rid="bib27" ref-type="bibr">[27]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>, <xref rid="bib29" ref-type="bibr">[29]</xref>]. As outcome events can be expressed by the rate in the study population overall, and by the total number of chemotherapy cycles received, we chose to present both formats [<xref rid="bib30" ref-type="bibr">30</xref>]. With respect to study endpoints, TC is not an innocuous regimen even with G-CSF use, as 33.9% of G-CSF patients experienced at least one event related to the primary or secondary endpoint.</p>
              <p id="p0140">There are limitations with the current trial. Due to the study’s pragmatic nature it did not employ a double-blind design. It might be viewed as both limitations and strengths that the duration of ciprofloxacin was between 7 and 14 days depending on local standards, while the type, dose and duration of G-CSF were left to patient and physician choice. This was done to reflect the realities of clinical practice in a real-world setting. Similarly, many physicians do not adjust the dose of G-CSF based on weight [<xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>, <xref rid="bib33" ref-type="bibr">[33]</xref>] or may use shorter durations than identified in prior studies [<xref rid="bib34" ref-type="bibr">34</xref>]. Some studies cite patient age ≥65 as an important factor for increased risk of FN [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib26" ref-type="bibr">[26]</xref>, <xref rid="bib27" ref-type="bibr">[27]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>]. In our study the proportion of patients having FN was 35/339 (10.3%) vs. 14/119 (11.7%) for the &lt;65 and ≥ 65 subgroups (p-value = 0.24), respectively. In the current study, 22.5% of patients were ≥65, compared with 16% in the definitive TC approval trial [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib23" ref-type="bibr">23</xref>]. Our study also allowed patients to receive biosimilar formulations of filgrastim, again making the results more generalisable toward real-world practice.</p>
              <p id="p0145">Future studies are needed to evaluate primary FN prophylaxis from patient perspective, as there are considerable differences both in terms of toxicity and patient cost between these strategies. Growth factor support is expensive both in terms of direct (costs to the patient and/or the health care system) [<xref rid="bib6" ref-type="bibr">6</xref>] and indirect (paying health care staff to administer and/or to teach patients to self-administer subcutaneous injections) costs. G-CSF use may also be associated with clinically important adverse effects including local and systemic pain syndrome. In addition, future studies could evaluate the effect of cost effectiveness of different G-CSF products. For example, differences in patients (dose and duration of G-CSF used), between agents (filgrastim vs pegfilgrastim), between biosimilars and non-biosimilars and between insurance companies and Provincial tender-based contracts could give interesting comparisons. Ciprofloxacin, while relatively inexpensive, is associated with its own adverse effects, such as <italic>C. difficile</italic> infection. With all of these factors considered, the ideal prophylaxis regimen needs to consider not only clinical efficacy but cost and patient comfort/acceptability [<xref rid="bib35" ref-type="bibr">35</xref>].</p>
            </sec>
            <sec id="sec5">
              <label>5</label>
              <title>Conclusion</title>
              <p id="p0150">We have demonstrated that while our primary outcome of FN and hospitalisations did not reach statistical significance, G-CSF was superior to ciprofloxacin for reducing FN rates. In addition, treatment related hospitalisations also favoured G-CSF, but was not statistically significant. Finally, the gains in clinical benefits of G-CSF did not justify its high cost.</p>
            </sec>
            <sec id="sec6">
              <title>Role of the funding source</title>
              <p id="p0155">This work was supported by the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004390</institution-id><institution>Ottawa Hospital</institution></institution-wrap></funding-source> Department of Medicine Patient Quality and Safety Committee PQ&amp;I Project Grant with matched funding from the <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004390</institution-id><institution>Ottawa Hospital</institution></institution-wrap></funding-source> Division of Medical Oncology. Additional funding was obtained from Cancer Care Ontario: Clinical Programs and Quality Initiatives 2017 and 2018 grants to support expansion of REaCT trials to other cancer centres in Ontario and from the Canadian Institute of Health Research: SPOR grant. The Rethinking Clinical Trials (REaCT) Program platform at the <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004390</institution-id><institution>Ottawa Hospital</institution></institution-wrap></funding-source> is also supported by The <funding-source id="gs5"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004390</institution-id><institution>Ottawa Hospital</institution></institution-wrap></funding-source> Foundation and its generous donors.</p>
            </sec>
            <sec id="sec7">
              <title>Trial registration</title>
              <p id="p0160">ClinicalTrials.gov: <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT02173262" id="intref0020">NCT02173262</ext-link>, <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT02816112" id="intref0025">NCT02816112</ext-link>;</p>
            </sec>
            <sec id="sec8">
              <title>Author contributions</title>
              <p id="p0165">MC, DF, AAJ, LV, BH and JH designed the study and prepared the protocol. MC, AAJ, JMJ, JPH, JM, XZ, TN, MKFI, MS, DS, BB, AA, LP, NN, JH collected the data. MC acted as principal investigator, MS and DS coordinated data entry and GP did the statistical analysis. KT performed a cost-utility analysis, MC, MS, KT, DS, LV and GP had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. MC, DF, MS, KT, DS, LV and GP wrote the manuscript. All authors were involved in the critical review of the manuscript and approved the final version.</p>
            </sec>
            <sec id="sec9">
              <title>Data sharing</title>
              <p id="p0170">The de-identified dataset is available upon request and approval from the REB Board of Record.</p>
            </sec>
            <sec id="sec10">
              <title>Ethics committee approval</title>
              <p id="p0175">All procedures performed in studies involving human participants were in accordance with the ethical standards of each institutions Research Ethics Board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all trial participants included in the study. All data has been anonymised to protect the identities of subjects involved in the research.</p>
            </sec>
            <sec sec-type="COI-statement">
              <title>Declaration of competing interest</title>
              <p id="p0180">MC reports personal fees (honoraria) from <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source>. AAJ reports personal fees (honoraria or travel funds) from <funding-source id="gs8"><institution-wrap><institution-id institution-id-type="doi">10.13039/100016259</institution-id><institution>Mylan</institution></institution-wrap></funding-source>, Teva, <funding-source id="gs10"><institution-wrap><institution-id institution-id-type="doi">10.13039/100015693</institution-id><institution>Purdue</institution></institution-wrap></funding-source>, <funding-source id="gs11"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008021</institution-id><institution>BMS</institution></institution-wrap></funding-source>, <funding-source id="gs12">BI</funding-source>, <funding-source id="gs13"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008067</institution-id><institution>Genomic Health</institution></institution-wrap></funding-source>, PUMA, <funding-source id="gs14"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source>, <funding-source id="gs15"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>, Astra Zeneca, <funding-source id="gs16"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source> and Eli <funding-source id="gs17"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004312</institution-id><institution>Lilly</institution></institution-wrap></funding-source>, outside the submitted work. JPH reports institutional research funds from <funding-source id="gs18"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source> and <funding-source id="gs19"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008021</institution-id><institution>BMS</institution></institution-wrap></funding-source>, outside the submitted work. JM reports personal fees (honorarium) from <funding-source id="gs20"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source> and share ownership in Pacylex Pharmaceutical Inc, SMHeart Card Inc, and illumiSonics, outside the submitted work. TN reports personal fees (honoraria) from ARIAD, <funding-source id="gs21"><institution-wrap><institution-id institution-id-type="doi">10.13039/100016040</institution-id><institution>Takeda</institution></institution-wrap></funding-source> and Boehringer-Ingelheim, outside the submitted work. <funding-source id="gs22"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000957</institution-id><institution>AA</institution></institution-wrap></funding-source> reports personal fees (honorarium for advisory board participation) from <funding-source id="gs23"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source>, outside the submitted work. LP reports personal fees (honorarium from advisory board participation) from Serono Oncology, outside the submitted work. NN reports personal fees (honorarium) from <funding-source id="gs24"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004337</institution-id><institution>Roche</institution></institution-wrap></funding-source>, and institutional research funds from <funding-source id="gs25"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source>, outside the submitted work. BH reports consulting fees from Cornerstone Research, outside the submitted work. JFH reports consulting fees from <funding-source id="gs26"><institution-wrap><institution-id institution-id-type="doi">10.13039/100008021</institution-id><institution>BMS</institution></institution-wrap></funding-source>, <funding-source id="gs27"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source>, Eli-<funding-source id="gs28"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004312</institution-id><institution>Lilly</institution></institution-wrap></funding-source>, <funding-source id="gs29"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source> and <funding-source id="gs30"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004334</institution-id><institution>Merck</institution></institution-wrap></funding-source>, outside the submitted work. All other authors declare no competing interests.</p>
            </sec>
          </body>
          <back>
            <ref-list id="cebib0010">
              <title>References</title>
              <ref id="bib1">
                <label>1</label>
                <element-citation publication-type="journal" id="sref1">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jones</surname>
                      <given-names>S.E.</given-names>
                    </name>
                    <name>
                      <surname>Savin</surname>
                      <given-names>M.A.</given-names>
                    </name>
                    <name>
                      <surname>Holmes</surname>
                      <given-names>F.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer</article-title>
                  <source>J Clin Oncol</source>
                  <volume>24</volume>
                  <issue>34</issue>
                  <year>2006</year>
                  <fpage>5381</fpage>
                  <lpage>5387</lpage>
                  <pub-id pub-id-type="pmid">17135639</pub-id>
                </element-citation>
              </ref>
              <ref id="bib2">
                <label>2</label>
                <element-citation publication-type="journal" id="sref2">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Aapro</surname>
                      <given-names>M.S.</given-names>
                    </name>
                    <name>
                      <surname>Bohlius</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Cameron</surname>
                      <given-names>D.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours</article-title>
                  <source>Eur J Canc</source>
                  <volume>47</volume>
                  <issue>1</issue>
                  <year>2010</year>
                  <fpage>8</fpage>
                  <lpage>32</lpage>
                  <comment>2011</comment>
                </element-citation>
              </ref>
              <ref id="bib3">
                <label>3</label>
                <element-citation publication-type="journal" id="sref3">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Younis</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Rayson</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Thompson</surname>
                      <given-names>K.</given-names>
                    </name>
                  </person-group>
                  <article-title>Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis</article-title>
                  <source>Support Care Canc</source>
                  <volume>20</volume>
                  <issue>10</issue>
                  <year>2012</year>
                  <fpage>2523</fpage>
                  <lpage>2530</lpage>
                </element-citation>
              </ref>
              <ref id="bib4">
                <label>4</label>
                <element-citation publication-type="journal" id="sref4">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>T.J.</given-names>
                    </name>
                    <name>
                      <surname>Bohlke</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Lyman</surname>
                      <given-names>G.H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Recommendations for the use of WBC growth factors: American society of clinical Oncology clinical practice guideline update</article-title>
                  <source>J Clin Oncol</source>
                  <volume>33</volume>
                  <issue>28</issue>
                  <year>2015</year>
                  <fpage>3199</fpage>
                  <lpage>3212</lpage>
                  <pub-id pub-id-type="pmid">26169616</pub-id>
                </element-citation>
              </ref>
              <ref id="bib5">
                <label>5</label>
                <element-citation publication-type="book" id="sref5">
                  <source>National comprehensive cancer network clinical practice guidelines in Oncology (NCCN Guidelines)®: breast cancer version 2</source>
                  <year>2017</year>
                  <ext-link ext-link-type="uri" xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf" id="intref0035">https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</ext-link>
                </element-citation>
              </ref>
              <ref id="bib6">
                <label>6</label>
                <element-citation publication-type="book" id="sref6">
                  <person-group person-group-type="author">
                    <collab>CCO Drug Formulary</collab>
                    <collab>GCSF Working Group</collab>
                  </person-group>
                  <chapter-title>Cancer care Ontario GCSF recommendations</chapter-title>
                  <year>2016</year>
                  <ext-link ext-link-type="uri" xlink:href="https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/38561" id="intref0040">https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/38561</ext-link>
                </element-citation>
              </ref>
              <ref id="bib7">
                <label>7</label>
                <element-citation publication-type="other" id="sref7">
                  <person-group person-group-type="author">
                    <collab>Amgen Canada Inc.</collab>
                  </person-group>
                  <article-title>Product monograph (filgrastim)</article-title>
                  <ext-link ext-link-type="uri" xlink:href="http://pi.amgen.com/%7E/media/amgen/repositorysites/pi-amgen-com/neupogen/neupogen_pi_hcp_english.ashx" id="intref0045">http://pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/neupogen/neupogen_pi_hcp_english.ashx</ext-link>
                </element-citation>
              </ref>
              <ref id="bib8">
                <label>8</label>
                <element-citation publication-type="other" id="sref8">
                  <person-group person-group-type="author">
                    <collab>Amgen Canada Inc.</collab>
                  </person-group>
                  <article-title>Product monograph (pegfilgrastim)</article-title>
                  <ext-link ext-link-type="uri" xlink:href="http://pi.amgen.com/%7E/media/amgen/repositorysites/pi-amgen-com/neulasta/neulasta_pi_hcp_english.ashx" id="intref0050">http://pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/neulasta/neulasta_pi_hcp_english.ashx</ext-link>
                </element-citation>
              </ref>
              <ref id="bib9">
                <label>9</label>
                <element-citation publication-type="journal" id="sref9">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Altwairgi</surname>
                      <given-names>A.K.</given-names>
                    </name>
                    <name>
                      <surname>Hopman</surname>
                      <given-names>W.M.</given-names>
                    </name>
                    <name>
                      <surname>Mates</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia</article-title>
                  <source>Curr Oncol</source>
                  <volume>20</volume>
                  <issue>3</issue>
                  <year>2013</year>
                  <fpage>e171</fpage>
                  <lpage>e179</lpage>
                  <pub-id pub-id-type="pmid">23737687</pub-id>
                </element-citation>
              </ref>
              <ref id="bib10">
                <label>10</label>
                <element-citation publication-type="journal" id="sref10">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hilton</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Vandermeer</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Sienkiewicz</surname>
                      <given-names>M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients</article-title>
                  <source>Support Care Canc</source>
                  <volume>26</volume>
                  <issue>7</issue>
                  <year>2018</year>
                  <fpage>2323</fpage>
                  <lpage>2331</lpage>
                </element-citation>
              </ref>
              <ref id="bib11">
                <label>11</label>
                <element-citation publication-type="journal" id="sref11">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fernandes</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Mazzarello</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Stober</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review</article-title>
                  <source>Breast Canc Res Treat</source>
                  <volume>161</volume>
                  <issue>1</issue>
                  <year>2017</year>
                  <fpage>1</fpage>
                  <lpage>10</lpage>
                </element-citation>
              </ref>
              <ref id="bib12">
                <label>12</label>
                <element-citation publication-type="journal" id="sref12">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Clemons</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Mazzarello</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Hilton</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC)</article-title>
                  <source>Support Care Canc</source>
                  <volume>27</volume>
                  <issue>4</issue>
                  <year>2019</year>
                  <fpage>1345</fpage>
                  <lpage>1354</lpage>
                </element-citation>
              </ref>
              <ref id="bib13">
                <label>13</label>
                <element-citation publication-type="journal" id="sref13">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fernandes</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Mazzarello</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Joy</surname>
                      <given-names>A.A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study</article-title>
                  <source>Support Care Canc</source>
                  <volume>26</volume>
                  <issue>9</issue>
                  <year>2018</year>
                  <fpage>3073</fpage>
                  <lpage>3081</lpage>
                </element-citation>
              </ref>
              <ref id="bib14">
                <label>14</label>
                <element-citation publication-type="journal" id="sref14">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fernandes</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Mazzarello</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Majeed</surname>
                      <given-names>H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review</article-title>
                  <source>Support Care Canc</source>
                  <volume>24</volume>
                  <issue>4</issue>
                  <year>2016</year>
                  <fpage>1583</fpage>
                  <lpage>1594</lpage>
                </element-citation>
              </ref>
              <ref id="bib15">
                <label>15</label>
                <element-citation publication-type="book" id="sref15">
                  <person-group person-group-type="author">
                    <name>
                      <surname>CADTH</surname>
                      <given-names>C.A.D.T.H.</given-names>
                    </name>
                  </person-group>
                  <chapter-title>Canadian drug expert committee final recommendation: filgrastim (Grastofil - Apotex Inc.) indications: preventions or treatment of neutropenia</chapter-title>
                  <year>2016</year>
                  <publisher-name>CADTH</publisher-name>
                </element-citation>
              </ref>
              <ref id="bib16">
                <label>16</label>
                <mixed-citation publication-type="other" id="sref16">Neulasta - Board Staff Statement of Allegations (Severed). <ext-link ext-link-type="uri" xlink:href="http://www.pmprb-cepmb.gc.ca/view.asp?ccid=838" id="intref0055">http://www.pmprb-cepmb.gc.ca/view.asp?ccid=838</ext-link> (September 28, 2016; [date last accessed)].</mixed-citation>
              </ref>
              <ref id="bib17">
                <label>17</label>
                <element-citation publication-type="journal" id="sref17">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Basulaiman</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Awan</surname>
                      <given-names>A.A.</given-names>
                    </name>
                    <name>
                      <surname>Fergusson</surname>
                      <given-names>D.</given-names>
                    </name>
                  </person-group>
                  <article-title>Creating a pragmatic trials program for breast cancer patients: rethinking Clinical Trials (REaCT)</article-title>
                  <source>Breast Canc Res Treat</source>
                  <year>2019</year>
                  <pub-id pub-id-type="doi">10.1007/s10549-019-05274-0</pub-id>
                </element-citation>
              </ref>
              <ref id="bib18">
                <label>18</label>
                <mixed-citation publication-type="other" id="oref0010g">ClinicalTrials.gov. A Multi-Cantre Study to Compare Granulocyte-colony Stimulating Factors to Antibiotics for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induced Febrile Neutropenia REaCT-TC2. https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0006DI3&amp;selectaction=Edit&amp;uid=U0001VRU&amp;ts=50&amp;cx=-ochws7.</mixed-citation>
              </ref>
              <ref id="bib19">
                <label>19</label>
                <element-citation publication-type="journal" id="sref19">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kim</surname>
                      <given-names>S.Y.</given-names>
                    </name>
                    <name>
                      <surname>Miller</surname>
                      <given-names>F.G.</given-names>
                    </name>
                  </person-group>
                  <article-title>Informed consent for pragmatic trials--the integrated consent model</article-title>
                  <source>N Engl J Med</source>
                  <volume>370</volume>
                  <issue>8</issue>
                  <year>2014</year>
                  <fpage>769</fpage>
                  <lpage>772</lpage>
                  <pub-id pub-id-type="pmid">24552326</pub-id>
                </element-citation>
              </ref>
              <ref id="bib20">
                <label>20</label>
                <element-citation publication-type="journal" id="sref20">
                  <person-group person-group-type="author">
                    <name>
                      <surname>de Naurois</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Novitzky-Basso</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Gill</surname>
                      <given-names>M.J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Management of febrile neutropenia: ESMO clinical practice guidelines</article-title>
                  <source>Ann Oncol</source>
                  <volume>21</volume>
                  <issue>Suppl 5</issue>
                  <year>2010</year>
                  <fpage>v252</fpage>
                  <lpage>v256</lpage>
                  <pub-id pub-id-type="pmid">20555092</pub-id>
                </element-citation>
              </ref>
              <ref id="bib21">
                <label>21</label>
                <element-citation publication-type="journal" id="sref21">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sung</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Nathan</surname>
                      <given-names>P.C.</given-names>
                    </name>
                    <name>
                      <surname>Alibhai</surname>
                      <given-names>S.M.</given-names>
                    </name>
                  </person-group>
                  <article-title>Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection</article-title>
                  <source>Ann Intern Med</source>
                  <volume>147</volume>
                  <issue>6</issue>
                  <year>2007</year>
                  <fpage>400</fpage>
                  <lpage>411</lpage>
                  <pub-id pub-id-type="pmid">17876022</pub-id>
                </element-citation>
              </ref>
              <ref id="bib22">
                <label>22</label>
                <element-citation publication-type="journal" id="sref22">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lyman</surname>
                      <given-names>G.</given-names>
                    </name>
                    <name>
                      <surname>Yau</surname>
                      <given-names>L.</given-names>
                    </name>
                    <name>
                      <surname>Nakov</surname>
                      <given-names>R.</given-names>
                    </name>
                  </person-group>
                  <article-title>Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support</article-title>
                  <source>Ann Oncol</source>
                  <volume>29</volume>
                  <issue>9</issue>
                  <year>2018</year>
                  <fpage>1903</fpage>
                  <lpage>1910</lpage>
                  <pub-id pub-id-type="pmid">30099478</pub-id>
                </element-citation>
              </ref>
              <ref id="bib23">
                <label>23</label>
                <element-citation publication-type="journal" id="sref23">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jones</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Barlow</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Barrett-Lee</surname>
                      <given-names>P.</given-names>
                    </name>
                  </person-group>
                  <article-title>Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring</article-title>
                  <source>Br J Canc</source>
                  <volume>100</volume>
                  <issue>5</issue>
                  <year>2009</year>
                  <fpage>684</fpage>
                </element-citation>
              </ref>
              <ref id="bib24">
                <label>24</label>
                <element-citation publication-type="journal" id="sref24">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vaz-Luis</surname>
                      <given-names>I.</given-names>
                    </name>
                    <name>
                      <surname>Barroso-Sousa</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Di Meglio</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Avoiding peg-filgrastim prophylaxis during the paclitaxel portion of the dose-dense doxorubicin-cyclophosphamide and paclitaxel regimen: a prospective study</article-title>
                  <source>J Clin Oncol</source>
                  <year>2020</year>
                  <pub-id pub-id-type="doi">10.1200/jco.19.02484:Jco1902484</pub-id>
                </element-citation>
              </ref>
              <ref id="bib25">
                <label>25</label>
                <element-citation publication-type="journal" id="sref25">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>T.J.</given-names>
                    </name>
                    <name>
                      <surname>Bohlke</surname>
                      <given-names>K.</given-names>
                    </name>
                    <name>
                      <surname>Lyman</surname>
                      <given-names>G.H.</given-names>
                    </name>
                  </person-group>
                  <article-title>Recommendations for the use of WBC growth factors: American society of clinical Oncology clinical practice guideline update</article-title>
                  <source>J Clin Oncol</source>
                  <volume>33</volume>
                  <issue>28</issue>
                  <year>2015</year>
                  <fpage>3199</fpage>
                  <lpage>3212</lpage>
                  <pub-id pub-id-type="pmid">26169616</pub-id>
                </element-citation>
              </ref>
              <ref id="bib26">
                <label>26</label>
                <element-citation publication-type="journal" id="sref26">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Madarnas</surname>
                      <given-names>Y.</given-names>
                    </name>
                    <name>
                      <surname>Dent</surname>
                      <given-names>S.F.</given-names>
                    </name>
                    <name>
                      <surname>Husain</surname>
                      <given-names>S.F.</given-names>
                    </name>
                  </person-group>
                  <article-title>Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres</article-title>
                  <source>Curr Oncol</source>
                  <volume>18</volume>
                  <issue>3</issue>
                  <year>2011</year>
                  <fpage>119</fpage>
                  <lpage>125</lpage>
                  <pub-id pub-id-type="pmid">21655158</pub-id>
                </element-citation>
              </ref>
              <ref id="bib27">
                <label>27</label>
                <element-citation publication-type="journal" id="sref27">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vandenberg</surname>
                      <given-names>T.</given-names>
                    </name>
                    <name>
                      <surname>Younus</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Al-Khayyat</surname>
                      <given-names>S.</given-names>
                    </name>
                  </person-group>
                  <article-title>Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis</article-title>
                  <source>Curr Oncol</source>
                  <volume>17</volume>
                  <issue>2</issue>
                  <year>2010</year>
                  <fpage>2</fpage>
                  <lpage>3</lpage>
                </element-citation>
              </ref>
              <ref id="bib28">
                <label>28</label>
                <element-citation publication-type="journal" id="sref28">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Soong</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Haj</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Leung</surname>
                      <given-names>M.G.</given-names>
                    </name>
                  </person-group>
                  <article-title>High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide</article-title>
                  <source>J Clin Oncol</source>
                  <volume>27</volume>
                  <issue>26</issue>
                  <year>2009</year>
                  <fpage>e101</fpage>
                  <lpage>e102</lpage>
                  <pub-id pub-id-type="pmid">19652050</pub-id>
                </element-citation>
              </ref>
              <ref id="bib29">
                <label>29</label>
                <element-citation publication-type="journal" id="sref29">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Weycker</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Barron</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Edelsberg</surname>
                      <given-names>J.</given-names>
                    </name>
                  </person-group>
                  <article-title>Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis</article-title>
                  <source>BMC Health Serv Res</source>
                  <volume>14</volume>
                  <year>2014</year>
                  <fpage>189</fpage>
                  <pub-id pub-id-type="pmid">24767095</pub-id>
                </element-citation>
              </ref>
              <ref id="bib30">
                <label>30</label>
                <element-citation publication-type="journal" id="sref30">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fernandes</surname>
                      <given-names>R.</given-names>
                    </name>
                    <name>
                      <surname>Mazzarello</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Stober</surname>
                      <given-names>C.</given-names>
                    </name>
                  </person-group>
                  <article-title>Primary febrile neutropenia prophylaxis for patients who receive FEC-D chemotherapy for breast cancer: a systematic review</article-title>
                  <source>J Glob Oncol</source>
                  <issue>4</issue>
                  <year>2018</year>
                  <fpage>1</fpage>
                  <lpage>8</lpage>
                  <pub-id pub-id-type="doi">10.1200/jgo.2016.008540</pub-id>
                </element-citation>
              </ref>
              <ref id="bib31">
                <label>31</label>
                <element-citation publication-type="journal" id="sref31">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>B.</given-names>
                    </name>
                    <name>
                      <surname>Nagai</surname>
                      <given-names>S.</given-names>
                    </name>
                    <name>
                      <surname>Armitage</surname>
                      <given-names>J.O.</given-names>
                    </name>
                  </person-group>
                  <article-title>Regulatory and clinical experiences with biosimilar filgrastim in the US, the European Union, Japan, and Canada</article-title>
                  <source>Oncol</source>
                  <volume>24</volume>
                  <issue>4</issue>
                  <year>2019</year>
                  <fpage>537</fpage>
                </element-citation>
              </ref>
              <ref id="bib32">
                <label>32</label>
                <element-citation publication-type="journal" id="sref32">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Collins</surname>
                      <given-names>J.M.</given-names>
                    </name>
                    <name>
                      <surname>Fleming</surname>
                      <given-names>G.F.</given-names>
                    </name>
                    <name>
                      <surname>Christ</surname>
                      <given-names>T.N.</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparison of the incidence of febrile neutropenia in obese and normal weight breast cancer patients receiving myelosuppressive chemotherapy and prophylactic pegfilgrastim</article-title>
                  <source>J Oncol Pharm Pract</source>
                  <volume>25</volume>
                  <issue>5</issue>
                  <year>2019</year>
                  <fpage>1112</fpage>
                  <lpage>1118</lpage>
                  <pub-id pub-id-type="pmid">29768957</pub-id>
                </element-citation>
              </ref>
              <ref id="bib33">
                <label>33</label>
                <element-citation publication-type="journal" id="sref33">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Buchner</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Lammerich</surname>
                      <given-names>A.</given-names>
                    </name>
                    <name>
                      <surname>Abdolzade-Bavil</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers</article-title>
                  <source>Curr Med Res Opin</source>
                  <volume>30</volume>
                  <issue>12</issue>
                  <year>2014</year>
                  <fpage>2523</fpage>
                  <lpage>2533</lpage>
                  <pub-id pub-id-type="pmid">25251999</pub-id>
                </element-citation>
              </ref>
              <ref id="bib34">
                <label>34</label>
                <element-citation publication-type="journal" id="sref34">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Clemons</surname>
                      <given-names>M.</given-names>
                    </name>
                    <name>
                      <surname>Fergusson</surname>
                      <given-names>D.</given-names>
                    </name>
                    <name>
                      <surname>Simos</surname>
                      <given-names>D.</given-names>
                    </name>
                  </person-group>
                  <article-title>A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer</article-title>
                  <source>Ann Oncol</source>
                  <volume>31</volume>
                  <issue>7</issue>
                  <year>2020</year>
                  <fpage>951</fpage>
                  <lpage>957</lpage>
                  <pub-id pub-id-type="pmid">32325257</pub-id>
                </element-citation>
              </ref>
              <ref id="bib35">
                <label>35</label>
                <element-citation publication-type="journal" id="sref35">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fraser</surname>
                      <given-names>J.</given-names>
                    </name>
                    <name>
                      <surname>Steele</surname>
                      <given-names>N.</given-names>
                    </name>
                    <name>
                      <surname>Al Zaman</surname>
                      <given-names>A.</given-names>
                    </name>
                  </person-group>
                  <article-title>Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group</article-title>
                  <source>Eur J Canc</source>
                  <volume>47</volume>
                  <issue>2</issue>
                  <year>2011</year>
                  <fpage>215</fpage>
                  <lpage>220</lpage>
                </element-citation>
              </ref>
            </ref-list>
            <sec id="appsec1" sec-type="supplementary-material">
              <label>Appendix A</label>
              <title>Supplementary data</title>
              <p id="p0190">The following are the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia component 1</title></caption><media xlink:href="mmc1.docx"><alt-text>Multimedia component 1</alt-text></media></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Multimedia component 2</title></caption><media xlink:href="mmc2.docx"><alt-text>Multimedia component 2</alt-text></media></supplementary-material></p>
            </sec>
            <ack id="ack0010">
              <title>Acknowledgements</title>
              <p id="p0185">We are grateful for patients and their families for their assistance with this study, as well as physicians for approaching patients. Highest accrual by physician was: Clemons (215), Hilton (54), Meza-Junco (29), Price-Hiller (26), Joy (24), Mackey (17), Ng (16), Tonkin (16), Zhu (15), Awan (7), Ibrahim (6) and Verma (5).</p>
            </ack>
            <fn-group>
              <fn id="appsec2" fn-type="supplementary-material">
                <label>Appendix A</label>
                <p id="p0195">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.breast.2021.03.012" id="intref0030">https://doi.org/10.1016/j.breast.2021.03.012</ext-link>.</p>
              </fn>
            </fn-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
